Prevention of bleomycin-induced lung inflammation and fibrosis in mice by naproxen and JNJ7777120 treatment

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 308-316

  Rosa, Arianna Carolina ^a   Pini, Alessandro ^c   Lucarini, Laura ^b   Lanzi, Cecilia ^b   Veglia, Eleonora ^a   Thurmond, Robin L ^d   Stark, Holger ^e   Masini, Emanuela ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; 8 HYDROXYDEOXYGUANOSINE; BLEOMYCIN; COLLAGEN; CYCLOOXYGENASE 2; HISTAMINE H4 RECEPTOR ANTAGONIST; INTERLEUKIN 10; MALONALDEHYDE; MYELOPEROXIDASE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E; SMAD3 PROTEIN; SMAD4 PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA; 1 ((5 CHLORO 1H INDOL 2 YL)CARBONYL) 4 METHYLPIPERAZINE; 1-((5-CHLORO-1H-INDOL-2-YL)CARBONYL)-4-METHYLPIPERAZINE; 8 OXO 7 HYDRODEOXYGUANOSINE; 8-OXO-7-HYDRODEOXYGUANOSINE; ANTIINFLAMMATORY AGENT; DEOXYGUANOSINE; DRUG DERIVATIVE; INDOLE DERIVATIVE; PEROXIDASE; PIPERAZINE DERIVATIVE; PTGS2 PROTEIN, MOUSE;

AIRWAY RESISTANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BREATHING MUSCLE; CELL COUNT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; GOBLET CELL; LUNG FIBROSIS; LUNG INFLATION; MALE; MOUSE; MUSCLE THICKNESS; NONHUMAN; OSMOTIC PUMP; OXIDATIVE STRESS; PNEUMONIA; PROTEIN EXPRESSION; TREATMENT OUTCOME; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; LUNG; METABOLISM; PATHOLOGY; SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLEOMYCIN; COLLAGEN; CYCLOOXYGENASE 2; DEOXYGUANOSINE; DISEASE MODELS, ANIMAL; GOBLET CELLS; INDOLES; LUNG; MICE; MUSCLE, SMOOTH; NAPROXEN; OXIDATIVE STRESS; PEROXIDASE; PIPERAZINES; PNEUMONIA; PULMONARY FIBROSIS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84907207583     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.215152     Document Type: Article

References (40)

1. Alfranca A, López-Oliva JM, Genís L, López-Maderuelo D, Mirones I, Salvado D, Quesada AJ, Arroyo AG, and Redondo JM (2008) PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood 112:1120-1128.
2. Arafa HM, Abdel-Wahab MH, El-Shafeey MF, Badary OA, and Hamada FM (2007) Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. Eur J Pharmacol 564:181-189.
3. Bai TR and Knight DA (2005) Structural changes in the airways in asthma: observations and consequences. Clin Sci (Lond) 108:463-477.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Carter NJ (2011) Pirfenidone: in idiopathic pulmonary fibrosis. Drugs 71:1721-1732.
6. Chandler DB and Young K (1989) The effect of diclofenac acid (Voltaren) on bleomycin-induced pulmonary fibrosis in hamsters. Prostaglandins Leukot Essent Fatty Acids 38:9-14.
7. Chen HB, Rud JG, Lin K, and Xu L (2005) Nuclear targeting of transforming growth factor-beta-activated Smad complexes. J Biol Chem 280:21329-21336.
8. Cowden JM, Riley JP, Ma JY, Thurmond RL, and Dunford PJ (2010) Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines. Respir Res 11:86.
9. Davies HR, Richeldi L, and Walters EH (2003) Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev (3):CD003134.
10. du Bois RM (2010) Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 9:129-140.
11. Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, and Bacon KB (2002) Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(1) T cells. J Pharmacol Exp Ther 303:300-307.
12. Garbuzenko E, Nagler A, Pickholtz D, Gillery P, Reich R, Maquart FX, and Levi- Schaffer F (2002) Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis. Clin Exp Allergy 32:237-246.
13. Godot V, Arock M, Garcia G, Capel F, Flys C, Dy M, Emilie D, and Humbert M (2007) H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. J Allergy Clin Immunol 120:827-834.
14. Harrison JH, Jr and Lazo JS (1987) High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 243:1185-1194.
15. Hauber HP and Blaukovitsch M (2010) Current and future treatment options in idiopathic pulmonary fibrosis. Inflamm Allergy Drug Targets 9:158-172.
16. Kisseleva T and Brenner DA (2008) Fibrogenesis of parenchymal organs. Proc Am Thorac Soc 5:338-342.
17. Kohyama T, Yamauchi Y, Takizawa H, Kamitani S, Kawasaki S, and Nagase T (2010) Histamine stimulates human lung fibroblast migration. Mol Cell Biochem 337:77-81.
18. Leonardi A, Di Stefano A, Motterle L, Zavan B, Abatangelo G, and Brun P (2011) Transforming growth factor-b/Smad - signalling pathway and conjunctival remodelling in vernal keratoconjunctivitis. Clin Exp Allergy 41:52-60.
19. Leonardi A, Radice M, Fregona IA, Plebani M, Abatangelo G, and Secchi AG (1999) Histamine effects on conjunctival fibroblasts from patients with vernal conjunctivitis. Exp Eye Res 68:739-746.
20. Lodovici M, Casalini C, Cariaggi R, Michelucci L, and Dolara P (2000) Levels of 8-hydroxydeoxyguanosine as a marker of DNA damage in human leukocytes. Free Radic Biol Med 28:13-17.
21. Masini E, Bani D, Vannacci A, Pierpaoli S, Mannaioni PF, Comhair SA, Xu W, Muscoli C, Erzurum SC, and Salvemini D (2005) Reduction of antigen-induced respiratory abnormalities and airway inflammation in sensitized guinea pigs by a superoxide dismutase mimetic. Free Radic Biol Med 39:520-531.
22. Masini E, Lucarini L, Sydbom A, Dahlén B, and Dahlén S-E (2013) Histamine in asthmatic and fibrotic disorders, in Histamine H4 Receptor: A Novel Drug Target (Stark H ed) pp 145-171, Versita, London.
23. Moore BB and Hogaboam CM (2008) Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294:L152-L160.
24. Morgan RK, McAllister B, Cross L, Green DS, Kornfeld H, Center DM, and Cruikshank WW (2007) Histamine 4 receptor activation induces recruitment of FoxP31 T cells and inhibits allergic asthma in a murine model. J Immunol 178:8081-8089.
25. Mullane KM, Kraemer R, and Smith B (1985) Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 14:157-167.
26. Ohkawa H, Ohishi N, and Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358.
27. Paz Z and Shoenfeld Y (2010) Antifibrosis: to reverse the irreversible. Clin Rev Allergy Immunol 38:276-286.
28. Pini A, Shemesh R, Samuel CS, Bathgate RA, Zauberman A, Hermesh C, Wool A, Bani D, and Rotman G (2010) Prevention of bleomycin-induced pulmonary fibrosis by a novel antifibrotic peptide with relaxin-like activity. J Pharmacol Exp Ther 335:589-599.
29. Pini A, Viappiani S, Bolla M, Masini E, and Bani D (2012) Prevention of bleomycininduced lung fibrosis in mice by a novel approach of parallel inhibition of cyclooxygenase and nitric-oxide donation using NCX 466, a prototype cyclooxygenase inhibitor and nitric-oxide donor. J Pharmacol Exp Ther 341:493-499.
30. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, and Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788-824.
31. Richeldi L, Davies HR, Ferrara G, and Franco F (2003) Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev (3):CD002880.
32. Saltzman LE, Moss J, Berg RA, Hom B, and Crystal RG (1982) Modulation of sssagen production by fibroblasts. Effects of chronic exposure to agonists that increase intracellular cyclic AMP. Biochem J 204:25-30.
33. Sassoli C, Pini A, Chellini F, Mazzanti B, Nistri S, Nosi D, Saccardi R, Quercioli F, Zecchi-Orlandini S, and Formigli L (2012) Bone marrow mesenchymal stromal cells stimulate skeletal myoblast proliferation through the paracrine release of VEGF. PLoS One 7:e37512.
34. Schrier DJ, Kunkel RG, and Phan SH (1983) The role of strain variation in murine bleomycin-induced pulmonary fibrosis. Am Rev Respir Dis 127:63-66.
35. Sivakumar P, Ntolios P, Jenkins G, and Laurent G (2012) Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Opin Pulm Med 18:462-469.
36. Stramer BM, Mori R, and Martin P (2007) The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol 127: 1009-1017.
37. Thrall RS, McCormick JR, Jack RM, McReynolds RA, and Ward PA (1979) Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol 95:117-130.
38. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, and Williams KN, et al. (2004) A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 309:404-413.
39. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210.
40. Zampeli E and Tiligada E (2009) The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 157:24-33.